Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.


Journal

Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R

Informations de publication

Date de publication:
27 09 2021
Historique:
pubmed: 14 8 2021
medline: 30 12 2021
entrez: 13 8 2021
Statut: ppublish

Résumé

The signal transducer and activator of transcription 6 (STAT6) is implicated in the pathogenesis of some lymphomas including primary central nervous system lymphomas (PCNSLs). The aim of this study was to investigate STAT6 expression and clinicopathologic features in 25 PCNSLs using immunohistochemistry with 2 different anti-STAT6 antibodies. One (YE361) recognizes the C-terminus domain of the STAT6 protein and the other (Y641) recognizes the phosphorylated form of the protein. The phosphorylated STAT6 form was not expressed in any of the cases studied whereas the YE361 STAT6 showed only cytoplasmic expression in 14 (56%) cases. This expression did not correlate with age, prognostic score, multiplicity, invasion of deep structures, response to treatment, disease recurrence, overall survival, or BCL6, BCL2, PD-L1, and CD8 expression. A STAT6 expression score showed a trend for correlating with clinical performance status. It also showed a positive correlation with MYC expression. Thus, the phosphorylated form of STAT6 was not found in the current series, while the YE361 STAT6 showed only cytoplasmic expression and was associated with expression of MYC.

Identifiants

pubmed: 34388250
pii: 6350867
doi: 10.1093/jnen/nlab080
doi:

Substances chimiques

STAT6 Transcription Factor 0
STAT6 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

830-834

Subventions

Organisme : BRIF
ID : BB-0033-00041

Informations de copyright

© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Auteurs

Georgia Karpathiou (G)

Pathology Department, University Hospital of Saint-Etienne, France.

Elise Ferrand (E)

Pathology Department, University Hospital of Saint-Etienne, France.

Florian Camy (F)

Pathology Department, University Hospital of Saint-Etienne, France.

Silvia-Maria Babiuc (SM)

Hematology and Cell Therapy Department, Lucien Neuwirth Cancer Institute, France.

Alexandra Papoudou-Bai (A)

Pathology Department, University Hospital of Ioannina, Ioannina, Greece.

Jean Marc Dumollard (JM)

Pathology Department, University Hospital of Saint-Etienne, France.

Jerome Cornillon (J)

Hematology and Cell Therapy Department, Lucien Neuwirth Cancer Institute, France.

Michel Peoc'h (M)

Pathology Department, University Hospital of Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH